RecruitingPhase 3NCT06973785

Non-Narcotic Pain Control After ACL Reconstruction


Sponsor

The Cleveland Clinic

Enrollment

30 participants

Start Date

Jul 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a double-blind randomized controlled trial of standard of care therapy, either oral ketorolac (experimental group) or oral oxycodone (control group) to demonstrate efficacy in reducing the percentage of narcotic doses taken and documenting the number of patients with no exposure to any narcotics (take zero oxycodone) after undergoing primary knee ACL reconstruction outpatient surgery.


Eligibility

Min Age: 15 YearsMax Age: 55 Years

Inclusion Criteria5

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 15-55 years
  • Primary Autograft ACL surgery
  • Ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts

Exclusion Criteria5

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for t the duration of the study
  • Male or female, aged 15-55 years
  • Primary Autograft ACL surgery
  • Ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdispense of study drug

• Cohort Group 1 (Experimental): ketorolac 10mg with rescue medication oxycodone 5mg All patients will be given acetaminophen

DRUGKetorolac

Patients will be randomized to either Ketorolac or Oxycodone


Locations(3)

Cleveland Clinic Coral Springs

Coral Springs, Florida, United States

Cleveland clinic sports medicine

Garfield, Ohio, United States

Cleveland Clinic

Strongsville, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06973785


Related Trials